Typical antipsychotic

Agitation in Delirium Management Market - Global Size, Share, Outlook, and Opportunity Analysis, 2016-2020 & 2021-2027 - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 26, 2021

The "Agitation in Delirium Management Market - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Agitation in Delirium Management Market - Size, Share, Outlook, and Opportunity Analysis, 2020 - 2027" report has been added to ResearchAndMarkets.com's offering.
  • This report provides an in-depth analysis of global agitation in delirium management market, provides market size (US$ Million), and compound annual growth rate (CAGR %) for the forecast period (2020-2027), considering 2019 as the base year
    Research institutes and market players are indulged in conducting research and development activities for testing the safety and efficacy of the drugs for the treatment of agitation in delirium in critically ill ICU patients.
  • For instance, in 2017, researchers at the University of California, San Diego, reported that sleep deprivation post-surgery causes delirium (confusion) in patients in the intensive care unit (ICU).
  • Market players are indulged in launching new first-generation antipsychotic drugs for the treatment of delirium, which is expected to spur the growth of the global agitation in delirium management market.

Newron Completes Enrollment of Explanatory Safety and Efficacy Study With Evenamide in Schizophrenia Patients

Retrieved on: 
Thursday, January 21, 2021

Enrollment to the study has been completed with 138 patients randomized to treatment with placebo, 7.5 mg BID, or 15 mg BID of evenamide at study centers in the United States and India.

Key Points: 
  • Enrollment to the study has been completed with 138 patients randomized to treatment with placebo, 7.5 mg BID, or 15 mg BID of evenamide at study centers in the United States and India.
  • The proposed phase III clinical trial program with evenamide targets patients with schizophrenia experiencing worsening of psychosis on atypical antipsychotics, and treatment-resistant patients not responding to clozapine.
  • Evenamide has the potential to be first add-on therapy for the treatment of patients with positive symptoms of schizophrenia.
  • Newron is also developing evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia.

DGAP-News: Newron completes enrollment of explanatory safety and efficacy study with evenamide in schizophrenia patients

Retrieved on: 
Thursday, January 21, 2021

Enrollment to the study has been completed with 138 patients randomized to treatment with placebo, 7.5 mg BID, or 15 mg BID of evenamide at study centers in the United States and India.

Key Points: 
  • Enrollment to the study has been completed with 138 patients randomized to treatment with placebo, 7.5 mg BID, or 15 mg BID of evenamide at study centers in the United States and India.
  • The proposed phase III clinical trial program with evenamide targets patients with schizophrenia experiencing worsening of psychosis on atypical antipsychotics, and treatment-resistant patients not responding to clozapine.
  • Evenamide has the potential to be first add-on therapy for the treatment of patients with positive symptoms of schizophrenia.
  • Newron is also developing evenamide as the potential first add-on therapy for the treatment of patients with positive symptoms of schizophrenia.

Upsher-Smith Launches Haloperidol Tablets, USP

Retrieved on: 
Monday, January 13, 2020

Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.

Key Points: 
  • Elderly patients with dementia-related psychosis treated with antipsychotic drugs are at an increased risk of death.
  • Observational studies suggest that, similar to atypical antipsychotic drugs, treatment with conventional antipsychotic drugs may increase mortality.
  • Haloperidol is not approved for the treatment of patients with dementia-related psychosis (see WARNINGS).
  • Please refer to the full Prescribing Information, including Boxed Warning for Haloperidol Tablets, USP here .

Categorical Response and Clinical Relevance as Assessed in a Phase III Study of HP-3070 (Asenapine) Transdermal Patch for the Treatment of Schizophrenia to be Presented at the American Psychiatric Association 172nd Annual Meeting

Retrieved on: 
Monday, May 20, 2019

"Presented here are analyses supporting a potentially new way of administering antipsychotics using a transdermal drug delivery system that uses a patch placed on the skin.

Key Points: 
  • "Presented here are analyses supporting a potentially new way of administering antipsychotics using a transdermal drug delivery system that uses a patch placed on the skin.
  • The primary outcome data from the pivotal Phase III study of HP-3070 have been previously presented and demonstratedthe safety and efficacy of this approach in adults with schizophrenia.
  • New analyses examining response rates support the clinical relevance of these results, and may help the clinician in appraising this new option for their patients."
  • Asenapine is a second generation atypical antipsychotic currently available as a sublingual formulation for the treatment of schizophrenia in adults.

Neurocrine Biosciences Presents New Quality of Life Data from RE-KINECT, the Largest Real-World Screening Study of Possible Tardive Dyskinesia in Patients Treated with Antipsychotics

Retrieved on: 
Tuesday, May 8, 2018

Results from the RE-KINECT study showed that nearly 28 percent of patients treated with an antipsychotic had clinician-confirmed possible TD.

Key Points: 
  • Results from the RE-KINECT study showed that nearly 28 percent of patients treated with an antipsychotic had clinician-confirmed possible TD.
  • Over half of patients with clinician-confirmed possible TD were affected by uncontrollable movements in two or more body regions.
  • "It is important that psychiatrists and neurologists take these findings into consideration when managing patients treated with antipsychotic medications.
  • Now that we have approved treatment options for tardive dyskinesia, it is important to proactively screen patients for the symptoms of tardive dyskinesia and diagnose patients living with this condition."